JP Morgan Chase
GCVRZ

JP Morgan Chase’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

JP Morgan Chase’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-36,968
Closed -$13K – 5778
2017
Q3 		$13K Sell
36,968
-23,913
-39% -$8.86K ﹤0.01% 4691
2017
Q2 		$23K Hold
60,881
– – ﹤0.01% 4517
2017
Q1 		$27K Hold
60,881
– – ﹤0.01% 4672
2016
Q4 		$23K Hold
60,881
– – ﹤0.01% 4686
2016
Q3 		$16K Hold
60,881
– – ﹤0.01% 4237
2016
Q2 		$15K Sell
60,881
-1,500
-2% -$258 ﹤0.01% 4284
2016
Q1 		$7K Sell
62,381
-34,170
-35% -$3.7K ﹤0.01% 4331
2015
Q4 		$11K Hold
96,551
– – ﹤0.01% 4201
2015
Q3 		$18K Buy
96,551
+9,439
+11% +$3.21K ﹤0.01% 3841
2015
Q2 		$61K Buy
87,112
+37,311
+75% +$25.8K ﹤0.01% 3907
2015
Q1 		$33K Buy
+49,801
New +$34.8K ﹤0.01% 3962

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

JP Morgan Chase's GCVRZ Position: Q4 2017 in Review

JP Morgan Chase sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2017, closing a stake of 36,968 shares — an estimated $13K sold.

JP Morgan Chase first reported a position in GCVRZ in Q1 2015 and held it in 11 quarters. The position peaked at $61K in Q2 2015. 105 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2017.

  • JP Morgan Chase reported no remaining Sanofi Contingent Value Rights position as of Q4 2017 after selling out during the quarter.
  • JP Morgan Chase sold 36,968 Sanofi Contingent Value Rights shares in Q4 2017, an estimated $13K.
  • JP Morgan Chase first reported a position in Sanofi Contingent Value Rights in Q1 2015 and held it in 11 quarters.
  • JP Morgan Chase's Sanofi Contingent Value Rights position peaked at $61K in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2017.

Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.